Daily Anesthesiology Research Analysis
Analyzed 75 papers and selected 3 impactful papers.
Summary
Three studies stand out today for perioperative and critical care anesthesiology: a preregistered meta-analysis suggests albumin-based resuscitation may reduce mortality in septic shock; a large multicenter cohort shows frailty assessment adds predictive value for postoperative MACCE beyond RCRI; and a meta-analysis with trial sequential analysis supports preoperative nebulized magnesium sulfate to prevent postoperative sore throat.
Research Themes
- Fluid resuscitation strategies in septic shock
- Preoperative risk stratification and frailty assessment
- Airway complication prevention after general anesthesia
Selected Articles
1. Mortality effect of albumin fluid resuscitation in adults with septic shock: a systematic review and dual frequentist-bayesian meta-analysis of randomised trials.
Across seven RCTs (n=3,273), albumin-based resuscitation was associated with lower all-cause mortality in adults with septic shock (RR 0.90, 95% CI 0.83–0.99) with concordant Bayesian support (94.7% posterior probability). Heterogeneity was negligible and no subgroup effect modification was detected, but overall certainty was rated low due to indirectness and imprecision.
Impact: This meta-analysis revives the long-standing colloid-crystalloid debate by suggesting a plausible mortality benefit of albumin specifically in septic shock using rigorous dual frequentist-Bayesian methods.
Clinical Implications: For adults with septic shock, albumin may be considered when resuscitation targets are not achieved with crystalloids alone, while balancing cost and availability; definitive practice change awaits adequately powered, shock-specific RCTs.
Key Findings
- Seven RCTs (n=3,273) showed lower all-cause mortality with albumin-based resuscitation (RR 0.90, 95% CI 0.83–0.99).
- Bayesian analysis yielded a 94.7% posterior probability that albumin reduces mortality.
- Heterogeneity was minimal (I²=0%), and no subgroup showed effect modification by albumin formulation, dosing, or baseline serum albumin.
- Overall certainty was graded low due to indirectness (subgroup-derived data) and imprecision.
Methodological Strengths
- PRISMA-compliant and preregistered protocol with dual frequentist-Bayesian synthesis
- Random-effects modeling with prespecified subgroup analyses and negligible heterogeneity (I²=0%)
Limitations
- Indirectness: several data derived from septic shock subgroups rather than shock-specific trials
- Low certainty (GRADE) and imprecision; lack of individual patient data to explore heterogeneity
Future Directions: Conduct adequately powered, shock-specific RCTs comparing albumin vs. crystalloids with patient-centered outcomes (mortality, organ failure) and cost-effectiveness; explore phenotype-specific responses via IPD meta-analysis.
OBJECTIVE: To determine the effect of albumin-based fluid resuscitation on mortality in adults with septic shock. DESIGN: Systematic review and dual frequentist-Bayesian meta-analysis of randomised clinical trials (RCTs), following PRISMA guidelines and preregistered protocol (CRD420261325998). DATA SOURCES: PubMed, Embase, CENTRAL, and Scopus were searched from inception to February 2026. METHODS: Eligible RCTs comparing albumin-based resuscitation strategies versus crystalloid-based resuscitation in adults with septic shock were included. The primary outcome was all-cause mortality at the longest available follow-up (up to 90 days). The analysis utilised random-effects models, subgroup analyses, and Bayesian methods. RESULTS: Seven trials (n = 3273) were included. Three trials primarily recruited septic shock patients, while data from the remaining were derived from subgroups or extracted strata. At the longest available follow-up, albumin-based fluid resuscitation was associated with a statistically significant 10% reduction in the relative risk of all-cause mortality (RR 0.90, 95% CI 0.83-0.99; p = 0.02; I² = 0%). Bayesian analysis under the primary weakly informative prior yielded a posterior probability of mortality reduction of 94.7% (P[RR < 1.0]). Pre-specified subgroup analyses by albumin formulation, dosing strategy, and trial-level baseline serum albumin did not show evidence of effect modification. CONCLUSION: In adults with septic shock, albumin-based resuscitation strategies are associated with a statistically significant reduction in mortality at the longest available follow-up, with a directionally concordant Bayesian estimate. A mortality benefit is therefore plausible, but the supporting evidence is indirect and imprecise (GRADE: low certainty). Adequately powered trials specifically addressing albumin fluid resuscitation in septic shock are warranted.
2. Nebulized magnesium sulfate reduces postoperative sore throat following general anesthesia: a systematic review, meta-analysis, and trial sequential analysis.
Pooling 12 RCTs (n=1,023), preoperative nebulized magnesium sulfate markedly reduced postoperative sore throat at 24 hours (RR 0.25) with consistent benefits at earlier time points and no hemodynamic harm. A 225 mg dose performed similarly to higher doses, and trial sequential analysis supported the robustness of evidence.
Impact: Offers a simple, low-cost, and safe prophylaxis to a common, patient-centered postoperative complication with robust quantitative synthesis and sequential monitoring.
Clinical Implications: Consider integrating 225 mg nebulized magnesium sulfate preoperatively to reduce postoperative sore throat, especially in high-risk airway cases, within multimodal ERAS pathways.
Key Findings
- At 24 h, nebulized magnesium sulfate reduced POST by 75% (RR 0.25, 95% CI 0.14–0.42).
- Significant reductions at 2, 4, and 12 h; 225 mg was as effective as higher doses.
- No increase in hemodynamic adverse events; TSA confirmed sufficient information size.
- Heterogeneity dropped from I²=62% to 7% after excluding an outlier in sensitivity analysis.
Methodological Strengths
- PROSPERO-registered meta-analysis limited to RCTs with predefined outcomes
- Trial sequential analysis and thorough sensitivity/subgroup analyses
Limitations
- Moderate initial heterogeneity and variability in dosing/regimens across trials
- Limited impact on hoarseness and cough; small single-center RCTs may introduce bias
Future Directions: Head-to-head trials comparing doses and timing, evaluation in high-risk subgroups (e.g., difficult airway, prolonged intubation), and cost-effectiveness analyses.
BACKGROUND: Post-operative sore throat (POST) frequently complicates general anesthesia involving endotracheal intubation, affecting roughly 60% of individuals and markedly hindering postoperative recovery. The current systematic review and meta-analysis assessed both the safety profile and prophylactic efficacy of preoperative magnesium sulfate administered via nebulization against POST. METHODS: A systematic review and meta-analysis of randomized controlled trials (RCTs) comparing preoperative nebulized magnesium sulfate with placebo or normal saline for POST prevention in adults undergoing elective surgery under general anesthesia was conducted. The primary outcome was POST incidence at 24 h. Secondary outcomes included POST at 2, 4, 8, and 12 h, hoarseness, cough, and hemodynamic adverse events. PROSPERO registration: CRD420261308633. RESULTS: Twelve RCTs comprising 1,023 patients were included. Nebulized Magnesium Sulfate significantly reduced POST at 24 h compared to control (RR = 0.25; 95% CI: 0.14-0.42; p < 0.00001; I² = 62%). Sensitivity analysis excluding an outlier reduced heterogeneity (I² = 7%) while maintaining significance. Significant reductions were also observed at 2 h (RR = 0.43; 95% CI: 0.32-0.58), 4 h (RR = 0.38; 95% CI: 0.19-0.77), and 12 h (RR = 0.34; 95% CI: 0.14-0.79). Subgroup analysis demonstrated comparable efficacy between the 225 mg dose and higher doses, with no statistically significant difference observed. No significant reduction was observed for hoarseness (RR = 0.44; 95% CI: 0.17-1.18) or cough (RR = 0.39; 95% CI: 0.15-1.04), and no increased hemodynamic risk was detected. Trial sequential analysis confirmed robust evidence for POST prevention. CONCLUSION: The administration of preoperative nebulized magnesium sulfate serves as an effective and safe measure to decrease POST incidence among adult patients, thereby justifying its inclusion in standard perioperative management protocols.
3. Preoperative health status assessed with different scales and postoperative cardiac and cerebrovascular complications in older patients: A retrospective study of a large multicentre cohort.
In 7,996 older adults across 19 hospitals, preoperative ADL, EQ-5D-5L, MET, and FRAIL scores were each associated with 30-day MACCE and improved risk discrimination when added to RCRI. The highest AUC was achieved by RCRI-Plus (RCRI, age, anemia severity, surgery duration) augmented with FRAIL (AUC 0.724), highlighting the value of routine frailty assessment.
Impact: Demonstrates scalable gains in perioperative cardiovascular risk prediction by augmenting RCRI with geriatric assessments, particularly frailty, in a large multicenter cohort.
Clinical Implications: Incorporate brief frailty screening alongside RCRI to refine MACCE risk estimates and guide perioperative optimization, monitoring intensity, and shared decision-making.
Key Findings
- RCRI alone had modest discrimination for 30-day MACCE (AUC 0.610).
- Augmenting RCRI with age, anemia severity, and surgery duration (RCRI-Plus) improved AUC to 0.692.
- Adding geriatric scales further improved discrimination; RCRI-Plus + FRAIL achieved AUC 0.724.
- DeLong tests found no significant differences among models adding ADL, EQ-5D-5L, MET, or FRAIL, though FRAIL had the highest AUC.
Methodological Strengths
- Large multicenter cohort (n=7,996) with standardized preoperative assessments
- Comprehensive modeling including RCRI-Plus and comparison via AUC and DeLong tests
Limitations
- Retrospective design and low MACCE incidence may limit power and residual confounding
- No external validation outside Chinese tertiary centers; calibration and net benefit may vary by setting
Future Directions: Prospective validation and impact analyses integrating frailty into perioperative pathways; evaluate calibration, net reclassification, and decision-analytic utility across diverse systems.
BACKGROUND: Multiple scales are available to evaluate the health status of older surgical patients; however, their relative ability to predict postoperative major adverse cardiac and cerebrovascular events (MACCE) remains unclear. OBJECTIVE: To examine the association between preoperative health status, as measured by four commonly used scales, and 30-day postoperative MACCE in older surgical patients, and to compare their predictive performance and incremental value against the Revised Cardiac Risk Index (RCRI). DESIGN: A retrospective study of a large multicentre cohort. SETTING: Nineteen tertiary hospitals across China participating in a perioperative database. PATIENTS: Patients aged ≥65 years who underwent noncardiac, non-neurosurgical surgery between April 2020 and April 2022 were included in the analysis. The Activities of Daily Living (ADL), EuroQol Five-Dimension Five-Level (EQ-5D-5L), Metabolic Equivalent of Task (MET), FRAIL, and RCRI were evaluated preoperatively. MAIN OUTCOME MEASURE: The primary outcome was the occurrence of MACCE within 30 days after surgery, defined as any of the following: stroke, myocardial infarction, angina pectoris, congestive heart failure, cardiac arrest, or all-cause mortality. RESULTS: Among the 7996 patients, 126 (1.6%) experienced MACCE. Similar to the RCRI, the four health assessments were significantly associated with MACCE risk. The RCRI alone yielded an area under the curve (AUC) of 0.610 [95% confidence interval (CI): 0.563 to 0.658]. Incorporating each scale improved the predictive performance of the RCRI. The RCRI-Plus model, comprising RCRI, age, severity of anaemia, and surgical duration, achieved an AUC of 0.692 (95% CI: 0.643 to 0.741). Further addition of the four scales to the RCRI-Plus increased discrimination, with the highest AUC observed for the RCRI-Plus model incorporating FRAIL (AUC 0.724; 95% CI: 0.679 to 0.770). However, DeLong's test showed no significant differences between this model and the RCRI-Plus models incorporating ADL, EQ-5D-5L, or MET. CONCLUSIONS: Preoperative health status assessed by four geriatric scales was significantly correlated with postoperative MACCE and provided improved risk discrimination beyond the RCRI. Adding any of these assessments to the RCRI enhanced predictive performance, with FRAIL showing the greatest incremental benefit. These findings underscore the value of multidimensional health status evaluation for preoperative cardiac and cerebrovascular risk stratification, with frailty assessment warranting particular attention. TRIAL REGISTRY: ClinicalTrials.gov, NCT04911530.